Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
36 hedge funds and large institutions have $18M invested in Cellular Biomedicine Group, Inc. in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 4 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
22% more capital invested
Capital invested by funds: $14.7M → $18M (+$3.3M)
3% more funds holding
Funds holding: 35 → 36 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$544K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$324K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$79.6K |
| 4 |
State Street
Boston,
Massachusetts
|
+$56.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$47.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$224K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$123K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$60.5K |
| 4 |
SO
STRS Ohio
Columbus,
Ohio
|
-$24.1K |
| 5 |
Bank of New York Mellon
New York
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EA
26
Emerald Acquisition
Seattle,
Washington
| $28K | +$27.6K | +1,941 | New |
|
27
BlackRock
New York
| $27K | +$3.72K | +262 | +17% |
|
|
SO
28
STRS Ohio
Columbus,
Ohio
| $21K | -$24.1K | -1,700 | -53% |
|
29
Citigroup
New York
| $14K | -$3.21K | -226 | -19% |
|
30
BNP Paribas Financial Markets
Paris,
France
| $13.1K | +$3.28K | +231 | +34% |
|
31
Bank of America
Charlotte,
North Carolina
| $9K | +$4.75K | +335 | +102% |
|
32
Creative Planning
Overland Park,
Kansas
| $4K | – | – | – |
|
|
AIM
33
Acrospire Investment Management
Chicago,
Illinois
| $4K | +$4.26K | +300 | New |
|
34
Barclays
London,
United Kingdom
| $2K | +$2.14K | +151 | New |
|
|
TCIM
35
TIAA CREF Investment Management
New York
| $509 | – | – | – |
|
|
36
Goldman Sachs
New York
| – | -$224K | -18,703 | Closed |
|
|
CS
37
Credit Suisse
Zurich,
Switzerland
| – | -$123K | -10,311 | Closed |
|
|
TRCT
38
Tower Research Capital (TRC)
New York
| – | -$10K | -868 | Closed |
|
|
MFS
39
MSI Financial Services
Springfield,
Massachusetts
| – | -$1K | -100 | Closed |
|
CBMG Hedge Fund Activity: Q3 2016 in Review
36 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q3 2016, worth a combined $18M — up 22% from $14.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CBMG positions and 4 closed out — a net gain of 1 holder — while 16 added to existing stakes and 5 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $544K. The largest seller was Goldman Sachs, exiting entirely with an estimated $224K sold.
- 36 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q3 2016, up from 35 in Q2 2016.
- Funds reported $18M of Cellular Biomedicine Group, Inc. stock for Q3 2016, up 22% quarter-over-quarter.
- 5 funds opened new Cellular Biomedicine Group, Inc. positions in Q3 2016 and 4 closed out, a net change of +1 holder.
- The largest Cellular Biomedicine Group, Inc. buyer in Q3 2016 was Bridgeway Capital Management, an estimated $544K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q3 2016 was Goldman Sachs, an estimated $224K sold.
Based on aggregated 13F filings for Q3 2016.